Wolfgang Miesbach /LinkedIn
Sep 16, 2025, 02:44
Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“First reported inhibitor development in haemophilia A gene therapy Presented by Davide Matino at BIC meeting at Phase 3 giroctocogene fitelparvovec (AAV6, 3×10¹³ vg/kg, n=74).
Patient Profile:
- Genetic: Intron 22 inversion
- History: ITP + splenectomy
- Comorbidities: HCV & HIV co-infection
- Experience: 6,000 exposure days with FVIII
Clinical Timeline:
- Peak FVIII (day 75 after gene therapy): 441.7%
- Post-infusion: Multiple steroid courses for ↑ALT/AST
- Inhibitor development more than 1 year after treatment”
More recent insights on Hemostasis Today.
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications
-
Sep 17, 2026, 15:19Conan McIlwrath: The Haemophilia Society Engages With IBCA
-
Sep 17, 2026, 15:06Eleftheria Hatzimichael: A Contemporary Diagnostic Approach to Inherited Microcytic Anemias